The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Health and Me on MSN4d
FDA Approves ‘Spravato’ Nasal Spray As A Standalone Depression TreatmentWe have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback